Valencia GA, Rioja P, Morante Z, Ruiz R, Fuentes H, Castaneda CA, Vidaurre T, Neciosup S, Gomez HL. Immunotherapy in triple-negative breast cancer: A literature review and new advances. World J Clin Oncol 2022; 13(3): 219-236 [PMID: 35433291 DOI: 10.5306/wjco.v13.i3.219]
Corresponding Author of This Article
Guillermo Arturo Valencia, MD, Medical Assistant, Department of Medical Oncology, Instituto Nacional de Enfermedades Neoplásicas, Angamos Este Avenue 2520, Surquillo, Lima 15036, Peru. guillermo.valencia.mesias@gmail.com
Research Domain of This Article
Oncology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Oncol. Mar 24, 2022; 13(3): 219-236 Published online Mar 24, 2022. doi: 10.5306/wjco.v13.i3.219
Immunotherapy in triple-negative breast cancer: A literature review and new advances
Guillermo Arturo Valencia, Patricia Rioja, Zaida Morante, Rossana Ruiz, Hugo Fuentes, Carlos A Castaneda, Tatiana Vidaurre, Silvia Neciosup, Henry L Gomez
Guillermo Arturo Valencia, Patricia Rioja, Zaida Morante, Rossana Ruiz, Hugo Fuentes, Carlos A Castaneda, Tatiana Vidaurre, Silvia Neciosup, Henry L Gomez, Department of Medical Oncology, Instituto Nacional de Enfermedades Neoplásicas, Lima 15036, Peru
Author contributions: All authors made a significant contribution to the review reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all of the following areas: drafting, critically reviewing the article, and giving final approval of the version to be published; all have agreed on the journal to which the review has been submitted and on all aspects of the work.
Conflict-of-interest statement: None to declare.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Guillermo Arturo Valencia, MD, Medical Assistant, Department of Medical Oncology, Instituto Nacional de Enfermedades Neoplásicas, Angamos Este Avenue 2520, Surquillo, Lima 15036, Peru. guillermo.valencia.mesias@gmail.com
Received: August 22, 2021 Peer-review started: August 22, 2021 First decision: November 11, 2021 Revised: November 23, 2021 Accepted: February 19, 2022 Article in press: February 19, 2022 Published online: March 24, 2022
Core Tip
Core Tip: Triple-negative breast cancer (TNBC) is an exceptionally heterogeneous disease and historically a cancer with limited treatment options other than chemotherapy. Recent advances in immunotherapy has changed the standard of care in selected groups, especially in metastatic TNBC. This article review continues the detailed, updated and comprehensive literature review regarding immunotherapy in TNBC, including the discussion of clinical trials in different scenarios (metastatic, neoadjuvant, adjuvant) and potential biomarkers to provide useful knowledge for medical oncologists and the medical community. Our goal is sharing updated information for TNBC which is considered an overlooked population with an enormous necessity of novel treatments and biomarkers.
